CAS: 53643-12-2; 4-Methylumbelliferyl Di-N-Acetyl-β-D-Chitobiose

该化合物是一种含氟基质基质,广泛用于酶实验,用于检测胆碱酯酶和β-N-乙基乙基己酰胺酶活动.在酶裂变后,该基质释放出荧光化合物4-甲基苯丙烯酯(4-MU),允许对酶动力学进行敏感和定量测量.该基质在涉及降解途径,真菌细胞壁研究以及淋巴储存紊乱研究的研究中具有特别宝贵的价值.该基质的特性和低背景荧光度使该基质成为活体和活体应用的可靠工具.该化合物在标准实验室条件下保持稳定,并与高通量筛选方法相容,在生物化学和生物医学研究中提供一致和再生结果.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2011195450-A1
    优先权日:2005-09-27
    标 题 :In Vitro Protein Synthesis Systems for Membrane Proteins that Include Adolipoproteins and Phospholipid Adolipoprotein Particles
    发明人:KUDLICKI WIESLAW; FLETCHER JULIA; KATZEN FEDERICO
    权利人:LIFE TECHNOLOGIES CORP
    摘要:In vitro protein synthesis systems and methods are provided that produce membrane proteins in soluble form. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include an apolipoprotein, in which higher yields of soluble protein are produced than in the absence of the apolipoprotein. Apolipoproteins useful in the present invention include naturally occurring apolipoproteins, as well as sequence variants of wild-type apolipoproteins, and engineered apolipoproteins. The apolipoproteins can be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein translation and at least one apolipoprotein biomolecule.

    专利号:WO-2007038755-A1
    优先权日:2005-09-27
    标 题:In vitro protein synthesis systems for membrane proteins that include apolipoproteins and phospholipid-apolipoprotein particles
    发明人:KUDLICKI WIESLAW; FLETCHER JULIA; KATZEN FEDERICO
    权利人:INVITROGEN CORP; KUDLICKI WIESLAW; FLETCHER JULIA; KATZEN FEDERICO
    摘要:In vitro protein synthesis systems and methods are provided that produce membrane proteins in soluble form. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include an apolipoprotein, in which higher yields of soluble protein are produced than in the absence of the apolipoprotein. Apolipoproteins useful in the present invention include naturally occurring apolipoproteins, as well as sequence variants of wild-type apolipoproteins, and engineered apolipoproteins. The apolipoproteins can be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein translation and at least one apolipoprotein biomolecule.

    专利号:US-6229055-B1
    优先权日:1996-04-12
    标题 :Synthesis of fluorinated xanthene derivatives
    发明人:KLAUBERT DIETER H; GEE KYLE R
    权利人:MOLECULAR PROBES INC
    摘要:Facile syntheses for fluorinated resorcinol and aminophenol derivatives are provided that yield isomer-free products in good yield. These novel methods use generally available precursors and standard laboratory reagents and equipment to reproducibly produce these synthetically useful reagents in relatively large quantities. The resulting fluorinated resorcinols and aniinophenols possess utility in the preparation of fluorinated fluorescein and rhodol dyes.

    专利号:US-7829669-B2
    优先权日:1999-06-28
    标 题:Catalytically active recombinant memapsin and methods of use thereof
    发明人:KOELSCH GERALD; TANG JORDAN J N; HONG LIN; GHOSH ARUN K; LIN XINLI
    权利人:OKLAHOMA MED RES FOUND; UNIV ILLINOIS
    摘要:Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1 ). The inhibition constant of OM99-2 is 1.6×10 −9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bond to this inhibitor was used to determine the three dimensional structure of the protein, as well as the importance of the various residues in binding. This information can be used by those skilled in the art to design new inhibitors, using commercially available software programs and techniques familiar to those in organic chemistry and enzymology, to design new inhibitors to memapsin 2, useful in diagnostics and for the treatment and/or prevention of Alzheimer's disease.

    专利号:US-7635749-B2
    优先权日:1999-12-24
    标题 :Methods and compositions for prolonging elimination half-times of bioactive compounds
    发明人:DENNIS MARK S; LOWMAN HENRY B; DELANO WARREN L
    权利人:GENENTECH INC
    摘要:Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein. In a preferred embodiment, a bioactive molecule having a short elimination half-time is incorporated as or into an active domain of the hybrid molecules of the invention, and the binding affinity of the peptide ligand domain prolongs the elimination half-time of the hybrid as compared to that of the bioactive molecule.

    专利号:US-8124794-B2
    优先权日:2002-04-17
    标题:Method for the asymmetric synthesis of beta-lactone compounds
    发明人:SMITH JEFFREY W; AXELROD FUMIKO; KRIDEL STEVEN J; ROMO DANIEL; PUROHIT VIKRAM; MA GIL
    权利人:SMITH JEFFREY W; AXELROD FUMIKO; KRIDEL STEVEN J; ROMO DANIEL; PUROHIT VIKRAM; MA GIL; SANFORD BURNHAM MED RES INST
    摘要:The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知